Corporate presentation
Logotype for Absci Corporation

Absci (ABSI) Corporate presentation summary

Event summary combining transcript, slides, and related documents.

Logotype for Absci Corporation

Corporate presentation summary

12 Nov, 2026

Platform and pipeline

  • Six-week lab-in-the-loop cycles; discovery estimated at $10–15M and 24 months, versus $50–100M and 5–6 years for large pharma.

  • Pipeline includes ABS-201 for pattern hair loss and endometriosis, ABS-202 for immunology and inflammation, and early-stage programs available for partnering.

  • Three clinical-stage programs have been delivered to date; the preclinical pipeline focuses on metabolism and immunology and inflammation.

  • More than 25 partnered programs to date, with collaboration focus on challenging targets or epitopes, differentiated target product profiles, and mono- or multispecific formats.

ABS-201 in pattern hair loss

  • Estimated 80M Americans have pattern hair loss: ~50M men and ~30M women; the presentation positions hair regrowth and limited treatment options as key unmet needs.

  • HEADLINE is a double-blind, placebo-controlled Phase 1/2a trial; all planned SAD cohorts were dosed, and MAD cohorts 1–3 were fully enrolled as of May 31, 2026.

  • Interim SAD results showed favorable safety across blinded cohorts and a half-life of at least 65 days; PK modeling supports potential for 2–3 injections over six months to maintain >90% receptor occupancy.

  • A 13-week interim proof-of-concept readout is expected in Dec 2026, with 26-week topline results expected in 2027.

  • Market research estimates a U.S. TAM >$25B and potential global TAM >$40B; the proposed profile targets infrequent dosing and potentially durable hair growth.

ABS-201 in endometriosis

  • Endometriosis treatment commonly includes hormonal therapies and surgery; the presentation describes chronic disease, persistent pain, and limitations in existing options.

  • PRLR antagonism is presented as a non-sex-hormone mechanism with potential effects on both lesion growth and pain; preclinical studies report reduced lesion formation and pain-related measures in mice.

  • The proposed opportunity addresses 9M U.S. patients, with potential peak sales >$4.5B; the presentation cites HMI-115 Phase 2 as clinical validation of the mechanism.

  • Phase 2 initiation is expected in mid-2027.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Absci